Announcements Trials
Browse Landscape

Phase

Phase NA 2Phase 2/3 1Phase 1/2 1

Status

Recruiting 1Completed 1

Sponsor Class

FED 1

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 40Neoplasms 36Prostatic Neoplasms 32Colorectal Neoplasms 22Carcinoma, Non-Small-Cell Lung 22Leukemia, Myeloid, Acute 21Precursor Cell Lymphoblastic Leukemia-Lymphoma 16Neoplasm Metastasis 14Polycystic Ovary Syndrome 13Lung Neoplasms 13Stomach Neoplasms 12Multiple Myeloma 11Carcinoma, Hepatocellular 11Recurrence 10Pancreatic Neoplasms 10Urinary Bladder Neoplasms 9Lymphoma 9Leukemia 9Myelodysplastic Syndromes 8Motor Activity 8Head and Neck Neoplasms 8Liver Neoplasms 7Leukemia, Myelogenous, Chronic, BCR-ABL Positive 7Esophageal Neoplasms 7Colonic Neoplasms 7Brain Neoplasms 7Pain 6Ovarian Neoplasms 6Lymphoma, Non-Hodgkin 6Lymphoma, Follicular 6

Interventions

Picibanil 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2/3 × Completed × Lymphatic Abnormalities × Clear all
NCT00010452 2015-03-25

Study of Picibanil (OK432) Sclerotherapy in Children With Macrocystic Lymphatic Malformations

FDA Office of Orphan Products Development

Phase 2/3 Completed
150 enrolled

Lymphangioma, Lymphangioma, Cystic, Lymphatic Abnormalities

Data powered by HemOnc (CC BY 4.0) Colophon âš¡